Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Combined modality therapy in NSCLC.

W Eberhardt1, S Bildat, S Korfee

  • 1Department of Internal Medicine (Cancer Research), University of Essen Medical School, Germany.

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|November 18, 2000
PubMed
Summary

Combined modality treatment is the standard of care for advanced non-small cell lung cancer (NSCLC). Future research will focus on personalized treatment protocols and novel therapies to improve patient outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Transverse resonance island buckets for synchrotron-radiation based electron time-of-flight spectroscopy.

The Review of scientific instruments·2018
Same author

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.

Leukemia·2017
Same author

Everolimus with paclitaxel and carboplatin as first-line treatment for metastatic large-cell neuroendocrine lung carcinoma: a multicenter phase II trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

Heart dose exposure as prognostic marker after radiotherapy for resectable stage IIIA/B non-small-cell lung cancer: secondary analysis of a randomized trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2017
Same author

[Exon-dependent Subgroup-analysis of the Non-interventional REASON-Study: PFS and OS in EGFR-mutated NSCLC Patients Treated with Gefitinib or Chemotherapy].

Pneumologie (Stuttgart, Germany)·2016
Same author

Open-label, randomized study of individualized, pharmacokinetically (PK)-guided dosing of paclitaxel combined with carboplatin or cisplatin in patients with advanced non-small-cell lung cancer (NSCLC).

Annals of oncology : official journal of the European Society for Medical Oncology·2016

Area of Science:

  • Medical Oncology
  • Thoracic Surgery
  • Radiation Oncology

Background:

  • Combined modality treatment is increasingly the standard of care for locally advanced non-small cell lung cancer (NSCLC).
  • Advancements in treatment techniques and supportive care reduce toxicity and improve patient compliance.
  • Multidisciplinary treatment groups are expanding in Europe for lung cancer management.

Purpose of the Study:

  • To review the current status and future directions of combined modality treatment for NSCLC.
  • To highlight the importance of treatment individualization and emerging therapeutic strategies.

Main Methods:

  • Review of current literature and clinical trial data.
  • Discussion of evolving treatment paradigms in NSCLC management.

Related Experiment Videos

Main Results:

  • Combined modality treatment offers improved outcomes for locally advanced NSCLC.
  • Ongoing phase-III trials are investigating the standard of care for various disease stages.
  • Personalized treatment approaches considering individual patient factors are crucial.

Conclusions:

  • Combined modality treatment is a cornerstone in managing locally advanced NSCLC.
  • Future research will explore novel agents (e.g., immunotherapy, targeted therapy) and personalized protocols.
  • The development of 'second-generation combined-modality protocols' is anticipated.